Results 121 to 130 of about 35,703 (223)

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk:Rationale and design of the ODYSSEY DM-INSULIN trial [PDF]

, 2017
Aims: The coadministration of alirocumab, a PCSK9 inhibitor for treatment of hypercholesterolaemia, and insulin in diabetes mellitus (DM) requires further study.
A. Letierce, Arsenault, B. Cariou, Brouwers, Cannon, Cannon, Cariou, Cariou, Catapano, Chillaron, Colhoun, Colhoun, Crosby, D. Müller-Wieland, de Ferranti, F.J. Tinahones, Feingold, G. Bigot, Ginsberg, H.M. Colhoun, J. Maroni, Jacobson, K.K. Ray, Kearney, Kereiakes, Koren, L. Aurand, L.A. Leiter, Langhi, Lee, Leiter, Lind, M. Bujas-Bobanovic, Mooradian, Piepoli, Preiss, R.R. Henry, Robinson, Roth, Ryden, S. Del Prato, Sattar, Schwartz, Sever, Tatlock, Toth, Turner, Verges, Wong, Wong   +49 more
core   +1 more source

Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease

Advanced Materials, Volume 38, Issue 17, 20 March 2026.
RNA interference (RNAi) nanomedicine revolutionizes treatment regimens for ischemic heart diseases by enabling tailored, sequence‐anchored gene regulation. This review highlights the recent advances in nanotechnology‐driven RNAi therapeutics for myocardial ischemia and discusses the key design principles that govern efficient delivery, providing ...
Han Gao, Da Pan, Hélder A. Santos
wiley   +1 more source

Contrasting effects of intracellular and extracellular human PCSK9 on inflammation, lipid alteration and cell death

Communications Biology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the major regulators of low-density lipoprotein receptor (LDLR). Information on role and regulation of PCSK9 in lung is very limited.
Aram Ghalali, Fahd Alhamdan, Swapna Upadhyay, Koustav Ganguly, Kjell Larsson, Lena Palmberg, Mizanur Rahman   +6 more
doaj   +1 more source

Hepatitis C virus relies on lipoproteins for its life cycle [PDF]

, 2016
Hepatitis C virus (HCV) infects over 150 million people worldwide. In most cases, HCV infection becomes chronic causing liver disease ranging from fibrosis to cirrhosis and hepatocellular carcinoma.
Alonzi, Tonino, DI CAPRIO, Giorgia, Fimia, Gian Maria, Grassi, Germana, Ippolito, Giuseppe, Tripodi, Marco   +5 more
core   +1 more source

Contribution of Gli1+ Adventitial Stem Cells to Smooth Muscle Cells in Atherosclerosis and Vascular Injury

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Gli1+ adventitial stem cells (ASCs) have been thought to generate smooth muscle cells (SMCs) in atherosclerosis. Using a dual‐recombinase lineage tracing to exclude ectopic labeling, Wang et al. found that Gli1+ ASCs do not contribute to SMCs in atherosclerotic plaques.
Haixiao Wang, Xiuzhen Huang, Jialing Mou, Enci Wang, Yan Li, Wenjuan Pu, Yao Xie, Xiaoling Guo, Lixin Wang, Maoping Chu, Bin Zhou, Chao Niu   +11 more
wiley   +1 more source

Structure‐Guided Engineering of a Cas12i Nuclease Unlocks Near‐PAMless Genome Editing

Advanced Science, Volume 13, Issue 17, 23 March 2026.
CRISPR‐Cas nucleases are limited by PAM requirements, restricting genome accessibility. Structure‐guided engineering of the compact Cas12i nuclease SF01 produced three variants with near‐PAMless, enabling efficient editing at diverse 5'‐NNTN‐3' sites. These nucleases expand the editable portion of the human genome more than fourfold, enabling efficient
Qitong Chen, Hanlin Gou, Chao Xu, Sihan Wang, Huitao Zhang, Minglei Song, Mengge Wang, Xingkun Ji, Xiaofei Wei, Yuanyan Tan, Hehua Quan, Pengyu Luo, Hanyu Shou, Pengpeng Liu, Yafeng Liang, Jian‐Kang Zhu   +15 more
wiley   +1 more source

Intrinsic Motivation [PDF]

, 2014
Employs a literature review to describe intrinsic motivation as the force behind pro-social behavior, or when individuals willingly engage in behavior that is costly to them but benefits others.
Brock, J. Michelle, Leonard, Kenneth L., Serneels, Pieter   +2 more
core   +1 more source

Impact of Monacolin K‐Containing Supplements on Lipid Profile: A Meta‐Analysis of Randomised Controlled Trials

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 2, March 2026.
ABSTRACT Background Natural products have gained attention as alternative strategies for managing dyslipidemia, particularly in individuals who are resistant or unwilling to use conventional pharmacotherapies. Monacolin K, a compound derived from natural sources, has demonstrated potential benefits in improving lipid profile indices across various ...
Tannaz Jamialahmadi, Elaheh Mirhadi, Sercan Karav, Prashant Kesharwani, Amirhossein Sahebkar   +4 more
wiley   +1 more source

PCSK9 peptide inhibitors [PDF]

Science-Business eXchange, 2014
Although many companies are chasing inhibitors of PCSK9 for lowering LDL cholesterol, antibodies or siRNAs that require injection are dominating the field. Roche's Genentech unit and a joint team from Pfizer and the University of Queensland are betting that peptides might provide an oral competitor.
openaire   +1 more source

Assessment of Quality of Care Provided for Patients Receiving Post‐Myocardial Infarction Care at Selected Cardiac Clinics in Sulaymaniyah: Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background According to global projections, by the year 2050, ischemic heart disease will remain the leading cause of cardiovascular deaths with hypertension as a leading modifiable risk factor for mortality. Improving quality care for patients with acute myocardial infarction (MI) is associated with improved outcomes. Aims There is inadequate
Banaz Sadiq Elias, Yara Sarwar Hamid, Mende Mensa Sorato   +2 more
wiley   +1 more source